Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix

1. Cramer anticipates JNJ's earnings report and ongoing litigation updates. 2. Drug stocks, including JNJ, face challenges from new federal leadership. 3. Positive news about a new JNJ drug could drive stock price up. 4. Cramer's sentiment suggests external factors may influence JNJ's performance. 5. Earnings reports from major banks indicate mixed market conditions.